(Career Enhancement Program) The goal of the Career Enhancement Program (CEP) of the MD Anderson Cancer Center Prostate Cancer SPORE (Prostate Cancer SPORE) is to develop a cadre of investigators dedicated to translational studies of human prostate cancer. It is directed by Dr. Gary E. Gallick and co-directed by Dr. Christopher J. Logothetis. The program will: 1) recruit innovative entry-level scientists to the Prostate Cancer SPORE to enhance the overall translational research capability of the SPORE and bring new techniques and talent to our program; 2) help these individuals develop the intellectual and technical skills required to be productive investigators in translational prostate cancer research; 3) teach these individuals basic principles of cancer biology not commonly included in clinical training or doctoral degree programs; and 4) guide the entry-level scientists in the development of competitive grant proposals in the area of translational prostate cancer research. The unique educational environment at MD Anderson will ensure that these goals will be met. At least two Career Enhancement awardees will be selected annually during the active funding period from qualified candidates within and outside MD Anderson who respond to a SPORE solicitation based on the defined criteria. Special emphasis will be placed on recruiting qualified women and members of minority populations whenever possible. In response to the previous critique, Dr. Logothetis will be actively involved in recruiting qualified physician/scientists to increase the number of MDs obtaining CEPs. Mentorship training will include principles of cancer biology, scientific methods, statistical analysis, biomedical communications, and strategies necessary to become successful in translational prostate cancer research. Several courses in The University of Texas Graduate School of Biomedical Sciences at Houston that encompass these disciplines are available to CEP recipients. The CEP recipients will be evaluated annually, and the selection process and training will be modified when appropriate. In addition, ?upward? evaluation by recipients to their mentors will also occur annually, with modifications to the program made, as necessary, in response to input of CEP recipients (see Appendix ?CEP Pilot Project Review Form? and ?CEP Evaluation Form? for evaluation criteria). Nine Career Development awards (now Career Enhancement awards) have been funded by the Prostate Cancer SPORE. Investigators receiving CDP awards wrote 53 publications. A total of 25 externally reviewed grant applications were funded. Of note, Dr. Hui-Kuan Lin, a CDP awardee, will submit a Developmental Research Program (DRP) project to the SPORE, reflecting the synergistic relationship between the CEP and DRP mechanisms. Dr. Ana Aparicio, genitourinary medical oncologist, is a CEP awardee.

Public Health Relevance

(Career Enhancement Program) The goal of the Career Enhancement Program of the MD Anderson Cancer Center Prostate Cancer SPORE is to develop a cadre of investigators dedicated to translational studies of human prostate cancer by recruiting innovative entry-level scientists to enhance the SPORE?s overall translational research capability, helping these individuals develop intellectual and technical skills required to be productive investigators, and teaching these individuals basic principles of cancer biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140388-07
Application #
9359413
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Hruszkewycz, Andrew M
Project Start
Project End
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
7
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Hong; Yang, Xu; Liu, Anna et al. (2018) ?-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. Carcinogenesis 39:158-169
Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461
Zanoaga, Oana; Jurj, Ancuta; Raduly, Lajos et al. (2018) Implications of dietary ?-3 and ?-6 polyunsaturated fatty acids in breast cancer. Exp Ther Med 15:1167-1176
Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707
Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106
Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76
Pan, Tianhong; Lin, Song-Chang; Yu, Kai-Jie et al. (2018) BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20:32-43
Yu-Lee, Li-Yuan; Yu, Guoyu; Lee, Yu-Chen et al. (2018) Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78:2911-2924
Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2018) Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142:2163-2174
Soundararajan, Rama; Aparicio, Ana M; Logothetis, Christopher J et al. (2018) Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69

Showing the most recent 10 out of 217 publications